Bayer Aktiengesellschaft

Bayer Healthcare Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Bayer Healthcare LLC

Klaus Mohrs

Romanis Fruchtmann

Christian Kohlsdorfer

Siegfried Raddatz

Reiner Muller-Peddinghaus

Pia Theisen-Popp

Elisabeth Perzborn

Reinhold Gehring

Friedel Seuter

Werner Heilmann

Stanislav Kazda

Walter Hubsch

Stefan Wohlfeil

Ulrich E Muller

Martin Beuck

Rudolf H Hanko

Matthias Muller-Gliemann

Michael Matzke

Thomas Kramer

Jurgen Dressel

Ulrich Niewohner

Herbert Diehl

Michael Lögers

Burkhard Fugmann

Mathias Berwe

Oliver Kuhn

Jana Lenz

Mike Matthäus

Jürgen Stiehl

Hans-Peter Bellemann

Matthias Müller-Gliemann

Pia Theisen

Hans-Peter Belleman

The present invention relates to a process for preparing 4-{4-[({[4-chloro-3-(trifluoro-methyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide and its tosylate salt.

Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide

The present invention relates to a novel process for preparing 8-methoxy-3-quinolonecarboxylic acids which are antibiotics having potent antibacterial action.

Method for producing 8-methoxy-quinolinecarboxylic acids

The invention relates to phenylacetic acid derivatives which are substituted by a five-membered nitrogen heterocycle bonded via an N atom. They are prepared by reaction of phenylacetic acid derivatives substituted with leaving groups with the appropriate nitrogen heterocycles and can be used as active substances in medicaments for the treatment of high blood pressure and atherosclerosis.

Heterocyclically substituted phenylacetic acid derivatives and their use

The invention relates to phenylacetic acid derivatives of the formula ##STR1## which are substituted by a five-membered nitrogen heterocycle bonded via an N atom. They are prepared by reaction of phenylacetic acid derivatives substituted with leaving groups with the appropriate nitrogen heterocycles and can be used as active substances in medicaments for the treatment of high blood pressure and atherosclerosis.

New phenylsulphonamide of the formula in which ##STR1## R.sup.1 represents a pyridyl, quinolyl or isoquinolyl radical which is unsubstituted or substituted by halogen, alkyl, cycloalkyl, alkoxy, cyano, nitro, halogenoalkyl, halogenoalkoxy, alkoxycarbonyl or alkylsulphonyl,

Antiflammatory quinolin methoxy phenylsulphonamides

For inhibiting lipoxygenzce, (quinolin-2-yl-methoxy) phenylacetic acid derivatives containing cyclic substituents of the formula ##STR1## in which A, Q, D, E, G, T and M are hydrogen or various radicals,

(Quinolin-2-yl-methoxy)phenylacetic acid derivatives containing cyclic

Inhibiting leucotriene synthesis in patients with novel substituted N-(quinolin-2-yl-methoxy)benzylsulphonyl-urea of the formula ##STR1## in which A, B, D, E, G, K and M each independently is H, OH, halogen, CF.sub.3, OCF.sub.3, COOH, alkyl, alkoxy, alkoxycarbonyl or aryl,

Substituted N-(quinolin-2-yl-methoxy) benzyl-sulphonylurea leukotriene

Inhibiting leucotriene synthesis in patients with novel disubstituted (quinolin-3-yl-methoxy)phenylacetic acid derivatives of the formula ##STR1## in which A, B, D, E, G, K and M each independently is H, OH, halogen, CF.sub.3, OCF.sub.3, COOH, alkyl, alkoxycarbonyl or aryl,

Leukotriene synthesis-inhibiting disubstituted (quinolin-2-yl-methoxy)

Substituted (quinolin-2-ylmethoxy)phenyl-thio-ureas of the formula ##STR1## in which A, B, D, E, G, K and M

Substituted (quinolin-2-yl-methoxy)phenylthioureas

New phenylsulphonamides of the formula in which ##STR1## R.sup.1 represents a pyridyl, quinolyl or isoquinolyl radical which is unsubstituted or substituted by halogen, alkyl, cycloalkyl, alkoxy, cyano, nitro, halogenoalkyl, halogenoalkoxy, alkoxycarbonyl or alkylsulphonyl,

Substituted phenylsulphonamides

Quinolinoxy phenylsulphonamides

Lipoxygenase-inhibiting and leukotriene-inhibiting substituted (quinolin-2-yl-methoxy)phenyl-N,N'-sulphonylureas of the formula ##STR1## and physiologically acceptable salts thereof.

Leukotriene-inhibiting substituted

Leucotriene synthesis inhibiting substituted 4-(quinolin-2-yl-methoxy)phenyl-acetic acid derivatives of the formula ##STR1## R.sup.1 --represents a group of the formula ##STR2## wherein Y--represents a group of the formula ##STR3## Z--represents norbornyl, or represents a group of the formula ##STR4## and A and B are identical or different and denote hydrogen, lower alkyl or halogen, and salts thereof.

Substituted 4-(quinolin-2-yl-methoxy)phenyl-acetic acid derivatives and

As lipoxygenase inhibitors, the novel .alpha.-substituted 4-(quinolin-2-yl-methoxy)phenyl-acetic acid and esters thereof of the formula ##STR1## in which R.sup.1 - stands for hydrogen, alkyl, arylalkyl, aryl or

Growing community of inventors

Wuppertal, Germany

Klaus Mohrs